Modality
Peptide
MOA
CDK4/6i
Target
CD38
Pathway
Neuroinflam
DLBCL
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
~Oct 2020
→ ~Jan 2022
Phase 3
Apr 2022
→ Sep 2029
Phase 3Current
NCT07412405
2,250 pts·DLBCL
2023-08→2025-11·Recruiting
NCT08091723
532 pts·DLBCL
2022-04→2029-09·Active
NCT05660745
1,192 pts·DLBCL
2024-02→2025-12·Recruiting
+1 more trial
6,785 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-11-274mo agoPh3 Readout· DLBCL
2025-12-193mo agoPh3 Readout· DLBCL
2029-09-173.5y awayPh3 Readout· DLBCL
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Active
P3
Recruit…
P3
Recruit…
P3
Recruit…
Catalysts
Ph3 Readout
2025-11-27 · 4mo ago
DLBCL
Ph3 Readout
2025-12-19 · 3mo ago
DLBCL
Ph3 Readout
2029-09-17 · 3.5y away
DLBCL
RecruitingActive|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07412405 | Phase 3 | DLBCL | Recruiting | 2250 | DAS28 |
| NCT08091723 | Phase 3 | DLBCL | Active | 532 | UPCR |
| NCT05660745 | Phase 3 | DLBCL | Recruiting | 1192 | PFS |
| NCT05047764 | Phase 3 | DLBCL | Recruiting | 2811 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| RHH-1969 | Roche | Approved | BET | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 |